What's Behind Merck's Disappointing Q4 Results?
You might say that Merck (NYSE: MRK) is experiencing malaise. Its shares sank 10% in 2020 while many stocks soared. The big drugmaker hasn't gotten off to a great start in 2021, having announced in January that it was giving up on its COVID-19 vaccine program.
Merck reported its fourth-quarter results before the market opened on Thursday. However, those results didn't do anything to give investors a warm and fuzzy feeling about the stock. Here's what's behind Merck's disappointing Q4 update.
Image source: Getty Images.
Source Fool.com
